Our Product

;

Learn more about Amarin's first commercialized product

We operate or partner to make our medicine available across the globe. To report an adverse event or a product complaint, or to request information about our products, please visit our contact us page. Please note, not all products are available in every country listed on the adverse events page. VASCEPA®/VAZKEPA®▼ (icosapent ethyl) is a prescription-only medicine This means it can only be prescribed by a suitably qualified healthcare professional who can assess its suitability for individual patients. ▼ Vazkepa is subject to additional monitoring in the EU. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions.

Learn More About Our Product

Learn more about Amarin’s product and how it reflects the work of our dedicated team, together with the contributions from many healthcare professionals and investors.

Region/Country

Download EU SmPC

Summary of Product Characteristics. This information is intended for EU residents only.

Download U.S. PI

Full Prescribing Information. This information is intended for U.S. residents only.

What To Do If You Experience Side Effects While Taking An Amarin Medicine

If you are taking a prescribed Amarin medicine and experience any side effects, you should immediately report these to your doctor, to another healthcare professional (such as a nurse or caretaker), or via the national reporting system.

Medical Inquiries

For medical questions, updated publications, information about our products or any other medical information, please submit your details here and a member of our Medical Affairs team will respond to you.

Leading A New Paradigm In Cardiovascular Health

The science behind the development of cardiovascular disease is complex. Our current treatment targets persistent cardiovascular risk reduction in patients at high- or very high risk - on statin therapy. We do this by focusing on science, research, passion and global knowledge to ensure we can stop heart disease from being a leading cause of death.

Pipeline

At Amarin, we’re committed to providing breakthrough treatments, scientific understanding and expertise.

CV Health

Putting cardiovascular health at the forefront of disease management

;

Investor Relations

A BOLD investment in cardiometabolic health

Keeping our investors informed about our progress in helping stop cardiovascular disease from being a leading cause of death is important to us. Click here for our investor presentations, events and financial results.

About Amarin

A new paradigm in cardiovascular health management

Amarin Corporation is focused on a BOLD vision to stop cardiovascular disease from being a leading cause of death. Find out more about our vision and how we lead the way to better care for those with cardiovascular disease.

Working at Amarin

A BOLD place for entrepreneurial careers

Are you interested in joining Amarin and being part of our BOLD vision to stop cardiovascular disease from being a leading cause of death worldwide? Click here for more information about our culture, career opportunities, benefits and more.

ALL-NP-00022 1/23

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT names and logos are trademarks of Amarin Pharmaceuticals Ireland Limited. | ALL-NP-00014 1/23

Get In Touch

Whether you’re a patient, a healthcare professional or a job seeker, you can find the best way to contact us from the options below. We’d love to hear from you:

Follow Amarin on our social channels for the latest company news, product campaigns and industry updates: